apremilast · Otezla

Small molecule

Also known as CC-10004

Approvedregulatory verdict

Evidence outlook

Approved: Psoriasis, Psoriatic Arthritis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (4)
US
  • Oral ulcers associated with Behcet's disease, in adults
Product first approved 2014Outside this platform's coverageFDA label
JP
  • Adult plaque psoriasis with inadequate response to topical therapies, and adult psoriatic arthritis (Celgene K.K., now Amgen)
Product first approved 2016biospace.com
EU
  • Psoriatic arthritis and moderate to severe plaque psoriasis in adults (later Behcet's oral ulcers and paediatric psoriasis); holder Amgen Europe B.V.
Product first approved 2015EMA
CA
  • • Plaque Psoriasis OTEZLA (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Limitations of Use: OTEZLA has not been studied and is therefore not indicated in combination with other systemic (conventional or biologic) therapies or phototherapy for psoriasis. • Psoriatic Arthritis OTEZLA (apremilast), alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response, intolerance, or...
Product first approved 2014Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (30)
Psoriasis
NCT05565560 · Amgen
2023-01-25 – 2026-09-03 · Plaque Psoriasis
What this study did
NCT06088199 · Amgen
2023-10-24 – 2026-08-12 · Plaque Psoriasis
What this study did
Psoriatic Arthritis
NCT05767047 · Amgen
2023-03-23 – 2036-03-17 · Behçet's Disease, Juvenile Psoriatic Arthritis
What this study did
NCT04804553 · Amgen
2022-03-17 – 2028-12-29 · Active Juvenile Psoriatic Arthritis
What this study did
NCT04610476 · University of Erlangen-Nürnberg Medical School
2020-10-19 – 2025-10-19 · Psoriatic Arthritis, Withdrawal, Reduction
What this study did
NCT06084663 · Humanis Saglık Anonim Sirketi
2023-02-15 – 2023-04-25 · Psoriasis and Psoriatic Arthritis
What this study did
NCT03191539 · Hospital Universitari Vall d'Hebron Research Institute
2017-11-02 – 2019-06-14 · Arthritis; Psoriasis (Etiology)
What this study did
NCT01307423 · Amgen
2010-12-09 – 2017-08-16 · Psoriatic Arthritis
What this study did
NCT01925768 · Amgen
2013-09-04 – 2016-11-17 · Psoriatic Arthritis
What this study did
NCT01690299 · Amgen
2012-10-01 – 2016-04-04 · Psoriasis, Psoriatic Arthritis
What this study did
Other / comorbidity
NCT04528082 · Amgen
2021-09-09 – 2030-12-17 · Behçet Disease
What this study did
NCT02735707 · UMC Utrecht
2016-04-11 – 2029-02 · Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP), Community Acquired Pneumonia, Severe, COVID-19, Respiratory Tract Infection Acute, Respiratory Tract Infections (RTI), SARS CoV 2 Infection
What this study did
NCT04227314 · University Hospital, Rouen
2022-04-10 – 2026-12 · Recurrent Aphtous Stomatitis
What this study did
NCT05174065 · Amgen
2022-03-08 – 2024-06-01 · Palmoplantar Pustulosis
What this study did
NCT04590586 · Amgen
2020-11-24 – 2021-08-03 · COVID-19
What this study did
NCT01583374 · Amgen
2012-05-02 – 2018-10-25 · Ankylosing Spondyloarthritis
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT00794274 · University of Cincinnati
2008-11 – 2011-12 · Sarcoidosis, Cutaneous Sarcoidosis
What this study did
Phase 2 (46)
Psoriasis
NCT03442088 · University Hospitals Cleveland Medical Center
2018-06-01 – 2021-09-30 · Plaque Psoriasis
What this study did
NCT00773734 · Amgen
2008-09-01 – 2015-05-20 · Psoriasis, Plaque-type Psoriasis
What this study did
NCT01200264 · Duke University
2010-09 – 2012-09 · Chronic Plaque Psoriasis
What this study did
NCT00521339 · Amgen
2007-08-01 – 2009-05-01 · Psoriasis-Type Psoriasis, Plaque-Type Psoriasis
What this study did
NCT00606450 · Amgen
2006-04-01 – 2007-05-01 · Psoriasis
What this study did
Psoriatic Arthritis
NCT01988103 · Amgen
2013-07-09 – 2015-12-15 · Psoriasis, Psoriatic Arthritis, Psoriasis Arthropatica
What this study did
NCT00456092 · Amgen
2007-03-05 – 2009-05-09 · Psoriatic Arthritis
What this study did
Other / comorbidity
NCT07029529 · Yale University
2026-05-12 – 2030-08 · Alcohol Use Disorder
What this study did
NCT04488081 · QuantumLeap Healthcare Collaborative
2020-07-31 – 2030-07-31 · COVID-19
What this study did
NCT07325266 · National Institute on Alcohol Abuse and Alcoholism (NIAAA)
2026-04-03 – 2027-07-31 · Alcohol Use Disorder, Alcohol Misuse
What this study did
NCT07850843 · Rashid Latif Medical College
2026-09-23 – 2026-10-31 · Chronic Urticaria, Chronic Spontaneous Urticaria, Chronic Inducible Urticaria
What this study did
NCT06509984 · Centre Hospitalier Universitaire de Nice
2024-08-06 – 2026-04-01 · Epidermolysis Bullosa Simplex, Genodermatosis
What this study did
NCT05875714 · Robert Micheletti
2022-01-13 – 2024-12-31 · Erythema Multiforme
What this study did
NCT03656666 · Oslo University Hospital
2019-09-24 – 2023-12-31 · Lichen Planus of Vulva, Female Genital Disease
What this study did
NCT04306965 · Tufts Medical Center
2020-08-01 – 2022-08-18 · Atopic Dermatitis
What this study did
NCT03160248 · Technical University of Munich
2017-07-05 – 2021-09-15 · Nummular Eczema, Eczema, Dermatitis Eczema, Nummular Dermatitis
What this study did
NCT04057937 · Amgen
2019-10-16 – 2021-06-07 · Palmoplantaris Pustulosis
What this study did
NCT03529955 · Tulane University
2018-06-12 – 2021-04-07 · Dermatomyositis, Adult Type
What this study did
NCT04161456 · Dr. Frank Behrens
2019-10-09 – 2021-02-08 · Acne Conglobata
What this study did
NCT03836885 · Sunnybrook Health Sciences Centre
2019-11-21 – 2020-04-22 · Oral Lichen Planus
What this study did
NCT03175549 · The Scripps Research Institute
2017-11-01 – 2020-04-01 · Alcohol Use Disorder
What this study did
NCT03036995 · Centre Hospitalier Universitaire de Nice
2017-03-20 – 2019-11-25 · Vitiligo
What this study did
NCT03239106 · Washington University School of Medicine
2017-12-01 – 2019-09-19 · Itch
What this study did
NCT04572997 · Kristian Reich
2018-11-29 – 2019-08-29 · Palmoplantar Pustulosis
What this study did
NCT03123016 · Icahn School of Medicine at Mount Sinai
2017-04-14 – 2019-08-05 · Vitiligo
What this study did
NCT02289417 · Amgen
2015-01-08 – 2019-06-03 · Ulcerative Colitis
What this study did
NCT03049267 · M.B.A. van Doorn
2017-02-02 – 2018-06-28 · Hidradenitis Suppurativa
What this study did
NCT02695212 · Florida Academic Dermatology Centers
2016-07 – 2017-08 · Hidradenitis Suppurativa
What this study did
NCT01250548 · Baylor Research Institute
2010-05 – 2014-06 · Rheumatoid Arthritis
What this study did
NCT01045551 · Julian M. Mackay-Wiggan
2010-06 – 2014-04 · Erythematotelangiectatic Rosacea, Papulopustular Rosacea
What this study did
NCT01200472 · University of Erlangen-Nürnberg Medical School
2010-08 – 2013-10 · Erosive Osteoarthritis of the Hand
What this study did
NCT01285310 · Amgen
2010-12-09 – 2012-09-10 · Rheumatoid Arthritis
What this study did
NCT00866359 · Amgen
2009-08-01 – 2012-05-01 · Behcet Syndrome
What this study did
NCT01041625 · Virginia Clinical Research, Inc.
2010-02 – 2012-02 · Lichen Planus
What this study did
NCT01204138 · Stanford University
2010-09 – 2011-12 · Arthritis, Rheumatoid
What this study did
NCT01393158 · Oregon Health and Science University
2009-05 – 2011-07 · Atopic Dermatitis
What this study did
NCT00701311 · Kenneth Peters, MD
2008-06 – 2011-03 · Prostatitis, Chronic Prostatitis With Chronic Pelvic Pain Syndrome
What this study did
NCT00814632 · Kenneth Peters, MD
2008-12 – 2011-02 · Vulvodynia
What this study did
NCT00869089 · University Hospitals Cleveland Medical Center
2008-09 – 2011-01 · Prurigo Nodularis
What this study did
NCT00944658 · Imperial College London
2009-08 – 2011-01 · Ankylosing Spondylitis
What this study did
NCT00997581 · Dartmouth-Hitchcock Medical Center
2010-04 – 2010-12 · Acute Gout
What this study did
NCT01074502 · University of North Carolina, Chapel Hill
2010-02 – 2010-10 · Acne
What this study did
NCT00931242 · Tufts Medical Center
2009-06 – 2010-03 · Atopic Dermatitis, Allergic Contact Dermatitis
What this study did
Phase 1/2 (3)
Other / comorbidity
NCT03576287 · Tanja Todberg, MD
2017-07-01 – 2019-12-01 · Prurigo Nodularis
What this study did
NCT00889421 · Oregon Health and Science University
2009-11 – 2011-06 · Uveitis
What this study did
NCT00708916 · NYU Langone Health
2008-06 – 2010-08 · Discoid Lupus Erythematosus
What this study did
Phase 1 (13)
Psoriasis
NCT07337434 · Syeda Sana Zaman
2025-12-25 – 2026-06-25 · Chronic Plaque Psoriasis
What this study did
NCT05601492 · Wake Forest University Health Sciences
2025-06 – 2026-02 · Psoriasis
What this study did
Psoriatic Arthritis
NCT07908641 · Amgen
2026-11-18 – 2027-01-10 · Psoriasis, Arthritis, Psoriatic, Oral Ulcer
What this study did
Other / comorbidity
NCT05703685 · National Institute of Mental Health (NIMH)
2023-06-22 – 2029-04-11 · Depression
What this study did
NCT06324435 · Yale University
2024-05-08 – 2026-08-30 · Alcohol Use Disorder
What this study did
NCT04811573 · Boehringer Ingelheim
2021-03-31 – 2021-08-18 · Healthy
What this study did
NCT02777554 · Amgen
2016-08-17 – 2016-11-22 · Healthy Volunteers
What this study did
NCT02802735 · Amgen
2016-06-22 – 2016-08-05 · Pharmacokinetics
What this study did
NCT02236988 · Amgen
2014-01-07 – 2014-09-11 · Healthy Volunteers
What this study did
NCT01634191 · Amgen
2012-02-01 – 2012-04-01 · Healthy Volunteer
What this study did
NCT01561963 · Amgen
2012-02-01 – 2012-04-01 · Healthy Subjects
What this study did
NCT01634178 · Amgen
2012-02-01 – 2012-03-01 · Healthy Volunteer
What this study did
Phase 4 (31)
Psoriasis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
NCT07432386 · Zarmeen Khawar
2026-05-14 – 2026-10-14 · Psoriasis, Pruritus
What this study did
NCT02144857 · University of Athens
2014-05-30 – 2023-12-31 · Psoriasis
What this study did
NCT06032858 · Ghurki Trust and Teaching Hospital
2022-03-06 – 2023-08-10 · Psoriasis
What this study did
NCT03022617 · University of Alabama at Birmingham
2017-01 – 2022-09-29 · Psoriatic Nail, Psoriasis Vulgaris, Psoriasis
What this study did
NCT04555707 · Derm Research, PLLC
2020-06-24 – 2021-09-30 · Psoriasis
What this study did
NCT03082729 · University of Pennsylvania
2017-04-24 – 2021-08-17 · Psoriasis, Cardiovascular Diseases
What this study did
NCT03453190 · Washington Dermatology Center
2018-02-25 – 2020-06-30 · Psoriasis
What this study did
NCT03553433 · University of Zurich
2018-06 – 2020-06 · Psoriasis of Scalp, Psoriasis Vulgaris
What this study did
NCT03587194 · Psoriasis Treatment Center of Central New Jersey
2018-07-23 – 2019-07-01 · Psoriasis
What this study did
NCT03146247 · Diamant Thaci
2017-10-23 – 2019-03-01 · Moderate to Severe Plaque Psoriasis
What this study did
NCT03000309 · Derm Research, PLLC
2016-12-29 – 2018-04-25 · Plaque Psoriasis
What this study did
NCT02425826 · Amgen
2015-04-20 – 2016-11-22 · Parapsoriasis
What this study did
NCT02400749 · Innovaderm Research Inc.
2015-05 – 2016-11 · Palmo-plantar Psoriasis
What this study did
NCT02412644 · Psoriasis Treatment Center of Central New Jersey
2015-05-28 – 2016-07 · Plaque Psoriasis
What this study did
Psoriatic Arthritis
NCT03747939 · Amgen
2018-12-31 – 2023-07-05 · Arthritis, Psoriatic
What this study did
NCT03783026 · Amgen
2019-02-06 – 2022-05-11 · Psoriatic Arthritis
What this study did
NCT04102449 · Medical University of Graz
2020-07-01 – 2022-02 · Psoriatic Arthritis
What this study did
NCT04515732 · Professor Mikkel Østergaard
2018-12-14 – 2021-10 · Psoriasis, Psoriatic Arthritis
What this study did
NCT02558361 · University of South Florida
2016-04 – 2016-10 · Psoriatic Arthritis
What this study did
Other / comorbidity
NCT06593197 · Dow University of Health Sciences
2025-01-01 – 2027-03-30 · Vitiligo
What this study did
NCT06260904 · All India Institute of Medical Sciences, Bhubaneswar
2024-01-26 – 2025-10-30 · Oral Lichen Planus
What this study did
NCT07708480 · Hayat Abad Medical Complex, Peshawar
2024-12-22 – 2025-05-22 · Hidradenitis Suppurativa
What this study did
NCT05926882 · Jinnah Postgraduate Medical Centre
2022-08-01 – 2023-06-20 · Alopecia Areata
What this study did
NCT03690544 · Mayo Clinic
2018-10-12 – 2021-07-14 · Recurrent Aphthous Stomatitis
What this study did
NCT03521687 · Icahn School of Medicine at Mount Sinai
2018-11-15 – 2021-02-12 · Central Centrifugal Cicatricial Alopecia
What this study did
NCT04822909 · Post Graduate Institute of Medical Education and Research, Chandigarh
2019-09-15 – 2020-06-30 · Erythema Nodosum Leprosum
What this study did
NCT03741933 · George Washington University
2019-02-28 – 2019-08-01 · Chronic Hand Dermatitis
What this study did
NCT03422640 · Bellevue Dermatology
2018-07-12 – 2019-01 · Frontal Fibrosing Alopecia
What this study did
Early phase / not applicable (5)
Psoriasis
NCT07366268 · Assiut University
2026-05 – 2028-03 · Psoriasis
What this study did
Psoriatic Arthritis
NCT07398651 · Tanta University
2026-12-30 – 2026-12-30 · Psoriatic Arthritis, Ultrasound Assessment, TNF
What this study did
NCT04645420 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2020-11-12 – 2023-02-10 · Psoriatic Arthritis
What this study did
Other / comorbidity
NCT02684123 · Icahn School of Medicine at Mount Sinai
2016-02 – 2017-09-15 · Alopecia Areata
What this study did
NCT01140503 · Stanford University
2010-02 – 2011-09 · Dermatomyositis
What this study did
Used as active comparator (10)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (8)
Psoriasis
NCT07712731 · Newsoara Biopharma Co., Ltd.
2025-04-18 – 2026-04-01 · Psoriasis
What this study did
NCT06588738 · Alumis Inc
2024-08-20 – 2025-12-18 · Plaque Psoriasis
What this study did
NCT06586112 · Alumis Inc
2024-07-25 – 2025-11-20 · Plaque Psoriasis
What this study did
NCT06088043 · Takeda
2023-11-06 – 2025-10-22 · Plaque Psoriasis
What this study did
NCT03168256 · Can-Fite BioPharma
2018-09-15 – 2022-04-27 · Plaque Psoriasis
What this study did
NCT03624127 · Bristol-Myers Squibb
2018-08-07 – 2020-09-02 · Psoriasis
What this study did
Phase 2/3 (1)
Psoriasis
NCT06863493 · SFA Therapeutics
2025-06-01 – 2026-09-01 · Psoriasis (PsO)
What this study did
Phase 1 (1)
Other / comorbidity
NCT02963779 · Eli Lilly and Company
2016-12 – 2017-10-05 · Healthy
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 4 (1)
Psoriasis
NCT03441789 · L.H. Kircik, M.D.
2017-09-18 – 2018-10-22 · Plaque Psoriasis
What this study did

Competitive landscape

This mechanism is crowded: 11 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Psoriasis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Apremilast (Otezla): this drugApprovedSmall moleculePDE4Reliable signal
NCT03701763: Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 (Baseline to Week 16): Apremilast 33.1% vs Placebo 11.5%
NCT03777436: Percentage of Participants With a Modified sPGA-G Response at Week 16 (Baseline and Week 16 of the Placebo-controlled Phase): Placebo-controlled Phase: Apremilast 30 mg 39.6% (95% CI 31.2 to 48) vs Placebo-controlled Phase: Placebo 19.5% (95% CI 12.7 to 26.3)
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT00195676: PGA 0/1 at 16 weeks after adalimumab retreatment: 89% in patients without relapse vs 69% in patients who relapsed; median time to relapse 141 days (178/285 stable-control patients relapsed)
NCT00237887: REVEAL: PASI 75 response rates of 71% after 16 weeks and 70% after 24 weeks of treatment with adalimumab 40 mg every other week.
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphaWeak signalNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Betamethasone Dipropionate Emollient Spray (Sernivo)ApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Bimekizumab (Bimzelx)ApprovedMonoclonal antibodyIL-17A/FReliable signal
NCT03412747: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 (Week 16): Bimekizumab 320 mg Q4W + Bimekizumab 320 mg Q4W/Q8W (RS) 86.2% vs Adalimumab (RS) 47.2%
NCT03370133: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 (Week 16): Bimekizumab 320 mg Q4W (RS) 85% vs Placebo (RS) 4.8% vs Ustekinumab (RS) 49.7%
Brodalumab (Siliq)ApprovedMonoclonal antibodyIL-17 receptor APartial signal
NCT02982005: Coprimary endpoints at week 12: PASI 75 and sPGA success achieved by 92.5% (brodalumab 210mg Q2W) vs 0% (placebo), significantly higher
Calcipotriene / Betamethasone Dipropionate Cream (Wynzora)ApprovedSmall moleculeVitamin D receptor + Glucocorticoid receptorPartial signal
NCT03802344: Percentage Change in mPASI (Modified Psoriasis Area and Severity Index) Score (8 Weeks): MC2-01 Cream -67.5% (Standard Error 20.8) vs Cal/BDP Combination -63.5% (Standard Error 22.2) vs Vehicle -11.7% (Standard Error 21.9)
NCT03308799: PGA treatment success at week 8: 37.4% with CAL/BDP cream (MC2-01) vs 22.8% with CAL/BDP topical suspension (P<0.0001) and 3.7% with vehicle (P<0.0001) (Stein Gold et al., J Drugs Dermatol 2021).
Calcipotriene / Betamethasone Dipropionate Foam (Enstilar)ApprovedSmall moleculeVitamin D receptor + Glucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Calcipotriol / Betamethasone Dipropionate Gel (Taclonex)ApprovedSmall moleculeVitamin D receptor + Glucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaReliable signal
NCT02326298: PASI 75 at Week 16 (CIMPASI-1): certolizumab pegol 200mg Q2W 66.5%, 400mg Q2W 75.8%, placebo 6.5% (P<0.0001 for both doses vs placebo).
NCT02326272: PASI 75 at Week 16 (CIMPASI-2): certolizumab pegol 200mg Q2W 81.4%, 400mg Q2W 82.6%, placebo 11.6% (P<0.0001 for both doses vs placebo).
Crisaborole (Eucrisa)
Approved(overall)
Small moleculePDE4
Reliable signal(overall)
No reviewed efficacy summary in this indication
Desoximetasone (Topicort Spray)ApprovedSmall moleculeGlucocorticoid receptor agonistPartial signal
NCT02618759: Number of Patients in Each Treatment That Have Clinical Success Based on IGA at Day 28 ± 2 (28 Days): DSXS1505 10/60 (16.7%) vs Placebo 3/59 (5.1%) missed phase 3 result · pivotal pending
NCT02932462: Clinical Success in Patients With Moderate and Severe Scalp Psoriasis (from baseline to study day 29): DSXS 1535 41/106 (38.7%) vs Placebo 43/126 (34.1%) missed phase 3 result · pivotal pending
Deucravacitinib (Sotyktu)ApprovedSmall moleculeTYK2Reliable signal
NCT04167462: The Percentage of Participants With sPGA Response of 0 or 1 (At week 16): Arm 1: BMS-986165 55.6% (95% CI 47.4 to 63.7) vs Arm 2: Placebo 6.8% (95% CI 1 to 12.5)
NCT03611751: The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA 0/1) (Week 16): BMS-986165 253/511 (49.5%) vs Placebo 22/255 (8.6%)
Difamilast (Moizerto / Adquey)
Approved(overall)
Small moleculePDE4
Partial signal(overall)
No reviewed efficacy summary in this indication
Etanercept (Enbrel)ApprovedProtein / enzyme therapeuticTNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha)Weak signal
NCT00111436: Primary endpoint (incidence of adverse events/lab changes) in this 912-patient open-label long-term safety extension (Leonardi et al. 2010, cited by this PMC review), exactly matching this NCT's registered enrollment (912) and design (open-label extension, safety of 50mg QW/BIW etanercept, 48-72 weeks): well tolerated, no significant AE/infection-rate difference between dose groups, no TB/opportunistic infection/demyelination/lymphoma cases.
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT02203032: Primary endpoint (NAVIGATE trial), mean number of visits Week 28-40 with IGA 0/1 and >=2-grade improvement: guselkumab 1.5 (SD 1.57, n=135) vs continued ustekinumab 0.7 (SD 1.26, n=133); row mean score test P<0.001.
NCT02207244: Week 16 co-primary endpoints (VOYAGE 2, NCT02207244): IGA 0/1 84.1% guselkumab vs 8.5% placebo (p<0.001); PASI 90 70.0% guselkumab vs 2.4% placebo (p<0.001)
Halobetasol Propionate Foam (Lexette)
ApprovedUS marketing discontinued
Small moleculeGlucocorticoid receptorReliable signal
NCT02742441: Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) (Day 15): 122-0551 Foam 30.7% vs Vehicle Foam 7.4%
NCT02368210: Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) (Day 15): 122-0551 Foam 25.3% vs Vehicle Foam 3.9%
Halobetasol Propionate Lotion (Bryhali)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT02514577: Percentage of Participants With Treatment Success at Week 8 (Week 8): IDP-122 Lotion 36.5% vs IDP-122 Vehicle Lotion 8.13%
NCT02515097: Percentage of Participants With Treatment Success at Week 8 (Week 8): IDP-122 Lotion 38.41% vs IDP-122 Vehicle Lotion 11.99%
Halobetasol Propionate / Tazarotene (Duobrii)ApprovedSmall moleculeGlucocorticoid receptor + retinoic acid receptorPartial signal
NCT02462122: Treatment success at week 8 (at least a 2-grade IGA improvement to clear or almost clear), halobetasol propionate 0.01%/tazarotene 0.045% lotion vs vehicle (study 2): 45.3% vs 12.5%, P<.001 (Gold et al., JAAD 2018; CT.gov posted 35.76%/6.98% and 45.33%/12.51%).
NCT02462070: Treatment success at week 8 (at least a 2-grade IGA improvement to clear or almost clear), halobetasol propionate 0.01%/tazarotene 0.045% lotion vs vehicle (study 1): 35.8% vs 7.0%, P<.001 (Gold et al., JAAD 2018; CT.gov posted 35.76%/6.98% and 45.33%/12.51%).
Icotrokinra (Icotyde)ApprovedPeptideIL-23 receptorReliable signal
NCT06095115: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16 (Week 16): JNJ-77242113 200 mg 64.7%
NCT06095102: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16 (Week 16): JNJ-77242113 200 mg 56.7% vs Placebo 5.8%
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT01177800: PASI 75 response at week 10: 81.0% infliximab (5 mg/kg) vs 2.2% placebo (P < 0.001)
NCT00106847: Primary endpoint (PASI 75 at week 10), EXPRESS II trial -- official title fetched directly from the CT.gov API for this NCT matches word-for-word ('...Infliximab Induction Therapy Followed by Multiple Regimens of Maintenance Infliximab Therapy in Patients With Plaque-Type Psoriasis'): infliximab 3mg/kg 70%, 5mg/kg 75%, vs placebo 2% (P<0.001).
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Ixekizumab (Taltz)ApprovedMonoclonal antibodyIL-17Reliable signal
NCT01695239: ACR20 response at week 24 (SPIRIT-P1): ixekizumab Q2W 62.1%, ixekizumab Q4W 57.9%, placebo 30.2% — significantly more responders in both ixekizumab arms than placebo.
NCT01474512: Percentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA) (Week 12): Ixe Q4W 76.4% | Ixe Q2W 81.8% vs Placebo 3.2%
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT02672852: Co-primary endpoints at Week 16 (IMMhance study): PASI 90 73% risankizumab vs 2% placebo; sPGA 0/1 84% risankizumab vs 7% placebo; both p<0.001
NCT02684370: PASI90 at Week 16 (UltIMMa-1 trial, NCT02684370): risankizumab 75.3% vs placebo 4.9% vs ustekinumab 42.0% (p<0.0001 vs both comparators)
Roflumilast (Daliresp)
Approved(overall)
Small moleculePDE4
not yet graded(overall)
No reviewed efficacy summary in this indication
Roflumilast (Zoryve Foam)ApprovedSmall moleculePDE4not yet gradedNo reviewed efficacy summary in this indication
Roflumilast (Zoryve)ApprovedSmall moleculePDE4Partial signal
NCT04211389: Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale (Week 8): Roflumilast Cream 0.3% 99/264 (37.5%) vs Vehicle Cream 9/131 (6.9%)
NCT04211363: Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8 (Baseline (Day 1) and Week 8): Rofumilast Cream 0.3% 108/255 (42.4%) vs Vehicle Cream 8/132 (6.1%)
Secukinumab (Cosentyx)ApprovedMonoclonal antibodyIL-17Reliable signal
NCT01358578: Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) . (12 wks): AIN457 150mg 219/327 (67.0%) | AIN457 300mg 249/323 (77.1%) vs Placebo 16/324 (4.9%)
NCT01365455: Percentage of Participants Who Achieved >75 or Higher (Psoriasis Area and Severity Index) PASI Score at 12 Weeks (12 weeks): AIN457 150 mg 71.6% | AIN457 300 mg 81.6% vs Placebo 4.5%
Spesolimab (Spevigo)ApprovedMonoclonal antibodyIL-36 receptorReliable signal
NCT03782792: Proportion of Patients With a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Pustulation Subscore of 0 Indicating no Visible Pustules at Week 1 (At Week 1.): Spesolimab 900 mg i.v SD 54.3% (95% CI 38.2% to 69.5%) vs Placebo 5.6% (95% CI 1% to 25.8%)
TapinarofApprovedSmall moleculeAryl hydrocarbon receptor, Aryl Hydrocarbon Receptor AgonistReliable signal
NCT03956355: Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation (Baseline to Week 12): Tapinarof (DMVT-505) 35.4% (Standard Error 2.75) vs Vehicle Cream 6% (Standard Error 2.08)
NCT03983980: Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation (Baseline to Week 12): Tapinarof (DMVT-505) Cream Group 40.2% (Standard Error 2.82) vs Vehicle Cream Group 6.3% (Standard Error 1.99)
Tildrakizumab (Ilumya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT01722331: Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) (Week 12 (or end of trial if prior to Week 12)): Tildrakizumab 200 mg (Part 1) 62.3% | Tildrakizumab 100 mg (Part 1) 63.8% vs Placebo (Part 1) 5.8%
NCT01729754: Percentage of Participants Achieving a Psoriasis Area Sensitivity Index 75% (PASI-75) Response at Week 12 (Part 1) (Week 12): Tildrakizumab 200 mg 65.6% | Tildrakizumab 100 mg 61.2% vs Placebo 5.8% | Etanercept 50 mg 48.2%
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40Reliable signal
NCT00307437: PASI 75 at Week 12 (intent-to-treat, PHOENIX 2 trial): placebo 15/410 vs ustekinumab 45 mg 273/409 vs ustekinumab 90 mg 311/411; p<0.001 for each dose vs placebo.
NCT00267969: PASI 75 at week 12: ustekinumab 45mg 67.1% vs placebo 3.1% (difference 63.9%, 95% CI 57.8-70.1, p<0.0001); ustekinumab 90mg 66.4% vs placebo 3.1% (difference 63.3%, 95% CI 57.1-69.4, p<0.0001).
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40Reliable signalFeatured results are non-efficacy only in this race
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Amdokitug (Yisaituo)Phase 3Monoclonal antibodyIL-17Anot yet gradedNo reviewed efficacy summary in this indication
Dimethyl Fumarate (Skilarence)Phase 3Small moleculeNrf2 pathway (fumaric acid ester)not yet gradedNo reviewed efficacy summary in this indication
EbdarokimabPhase 3Monoclonal antibodyIL-12/23 p40not yet gradedNo reviewed efficacy summary in this indication
EnvudeucitinibPhase 3Small moleculeTYK2Reliable signal
NCT06586112: PASI-75 at week 16 (ONWARD 1): 76.5% envudeucitinib vs 18.7% placebo; PASI-90: 59.9% vs 4.8%; PASI-100: 29.4% vs 0.9% (P<.0001 for all)
NCT06588738: ONWARD2, week 16 co-primary endpoints vs placebo (intention-to-treat, nonresponder imputation): PASI 75 70.4% with envudeucitinib 40 mg twice daily (n=433) vs 13.7% with placebo (n=211); sPGA 0/1 57.3% vs 5.7%; both P < 0.0001 (Cochran-Mantel-Haenszel). PASI 90: 53.1% vs 4.3%. Apremilast 30 mg twice daily (n=215): PASI 75 38.6%, sPGA 0/1 27.4% (Alumis AAD 2026 late-breaking presentation).
FadeucravacitinibPhase 3Small moleculeTYK2Partial signal
NCT06109818: PASI 75 at week 12: 77.3% (6 mg) and 78.6% (9 mg) vs 11.6% (placebo); primary endpoint achieved
GumokimabPhase 3Monoclonal antibodyIL-17APartial signal
NCT06066125: PASI 75 response at Week 12: 94.6% with gumokimab; PASI 100: 47.7%
HB0017Phase 3Monoclonal antibodyIL-17APartial signal
NCT05531682: Co-primaries PASI 90 and sPGA 0/1 at week 12: HB0017 300 mg (n=41) vs placebo (n=40), PASI 90 69.4% vs 1.0% and sPGA 0/1 78.2% vs 1.1%, both P<0.001. The registry lists three HB0017 dosing regimens and 160 participants; the abstract reports one regimen in 81 patients and gives no result for the other two regimens.
HS-10374Phase 3Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
HS-20137Phase 3Monoclonal antibodyIL-23 p19not yet gradedNo reviewed efficacy summary in this indication
ImsidolimabPhase 3Monoclonal antibodyIL-36 receptorPartial signalFeatured results are non-efficacy only in this race
LecankitugPhase 3Monoclonal antibodyIL-17A/Fnot yet gradedNo reviewed efficacy summary in this indication
MufemilastPhase 3Small moleculePDE4Partial signal
NCT04839328: PASI75 比例分别为 53.6% vs 16.0%,sPGA 0/1 率分别为 31.3% vs 6.4% (PASI75 at week 16: Hemay005 53.6% vs placebo 16.0%; sPGA 0/1: 31.3% vs 6.4%)
NetakimabPhase 3Monoclonal antibodyIL-17Reliable signal
NCT03390101: • The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment (week 12): BCD-085 Q2W 66/85 (77.6%) | BCD-085 Q4W 70/84 (83.3%) vs Placebo 0/44 (0.0%)
Nomelcitinib (D-2570)Phase 3Small moleculeTYK2Partial signal
NCT06278350: Primary endpoint PASI 75 at week 12: ≥85% in all three D-2570 dose groups vs 12.5% with placebo (p<0.001)
PicankibartPhase 3Monoclonal antibodyIL-23 p19Reliable signal
NCT06049810: PASI 90 maintenance at Week 56: 89.3% (100 mg) and 90.1% (200 mg) picankibart-maintenance groups vs 37.7% and 51.7% in the corresponding randomized-withdrawal groups; P < 0.0001 for both comparisons
NCT05645627: Co-primary 1, PASI 90 at week 16: 80.3% picankibart 200 mg vs 2.0% placebo (p<0.0001), met. Co-primary 2, sPGA 0/1 at week 16: 93.5% vs 13.1% (p<0.0001), met. Response rates from the JAAD paper; p-values from the Innovent release, as the paper abstract does not print them.
PiclidenosonPhase 3Small moleculeAdenosine A3 receptorPartial signal
NCT03168256: PASI 75 at week 16: 9.7% (3mg) vs 2.6% (placebo), p=0.037; linear improvement through week 32 (PASI 75: 19.6%)
NCT01265667: PASI 75 at week 12: CF101 2 mg 8.5% vs placebo 6.9%, P=0.621, tested at a 0.035 significance level (J Drugs Dermatol 2016). missed
Prifemilast (HPP737)Phase 3Small moleculePDE4Partial signal
NCT07712731: Co-primary endpoints at week 16, prifemilast 20 mg once daily vs apremilast 30 mg twice daily: PASI 75 64.6% vs 35.3% and sPGA 0/1 55.6% vs 31.3% (both P<0.0001) (2026-10-09).
NCT07712705: The placebo-controlled Phase 3 was positive per the sponsor, with responses kept through 52 weeks; figures were not given (2026-10-09).
Tirzepatide (Zepbound)Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
TQH3906Phase 3Small moleculeTYK2Partial signal
NCT06542614: At the recommended dose in the 209-patient study: PASI 75 above 90% and PASI 90 above 70% at 12 weeks
VunakizumabPhase 3Monoclonal antibodyIL-17Reliable signal
NCT04839016: Week 12 co-primary endpoints, vunakizumab 240 mg vs placebo (690 randomized 2:1): PASI 90 76.8% vs 0.9%; sPGA 0/1 71.8% vs 0.4%; both two-sided P < .0001 (Yan et al., J Am Acad Dermatol 2025).
NCT03463187: PASI 75 at week 12: 56.8% (40 mg), 65.8% (80 mg), 81.6% (160 mg), and 86.5% (240 mg) vs 5.4% placebo; P < .001 for all
ZasocitinibPhase 3Small moleculeTYK2Reliable signal
NCT06973291: LATITUDE Atlas, PASI 100 at week 16: more than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100), more than 2.5 times the response rate for deucravacitinib.
NCT06088043: Co-primary 1, sPGA 0/1 at week 16: 71.4% zasocitinib vs 10.7% placebo (p<0.001), met. Co-primary 2, PASI 75 at week 16 vs placebo: superiority shown per Takeda's topline release (response rates and p not printed in Takeda's releases), met. Ranked secondary, PASI 90 at week 16: 61.3% vs 5.0% placebo and 16.8% apremilast (p<0.001).
ALTO-101
Phase 2(overall)
Small moleculePDE4
not yet graded(overall)
No reviewed efficacy summary in this indication
MorcamilastPhase 2Small moleculePDE4not yet gradedNo reviewed efficacy summary in this indication
PALI-2108
Phase 2(overall)
Small moleculePDE4
Weak signal(overall)
No reviewed efficacy summary in this indication
SonelokimabPhase 2Antibody-derived scaffoldIL-17A/FReliable signal
NCT03384745: Primary endpoint, IGA 0/1 at week 12: placebo 0.0%, sonelokimab 30mg 48.1% (p<0.0001), 60mg 84.6% (p<0.0001), 120mg normal load 77.4% (p<0.0001), 120mg augmented load 88.2% (p<0.0001), secukinumab 300mg (active reference) 77.4% (p<0.0001) vs placebo.
LPX-TI641Phase 1Small moleculeTIM receptor (Treg-expanding)not yet gradedNo reviewed efficacy summary in this indication
S-4321Phase 1Multispecific antibodyPD-1 / FcγRIIb (dual)not yet gradedNo reviewed efficacy summary in this indication
IdrebormilastDiscontinuedSmall moleculePDE4Partial signal
NCT05375955: Plaque psoriasis primary, PGA clear or almost clear with a 2-point reduction at Week 12 vs vehicle (8.8%): 0.06% ointment 45.5% (risk difference 36.6, 95% CI 14.7 to 56.4, p=0.0003), 0.03% ointment 37.1% (risk difference 28.3, 95% CI 7.7 to 47.5, p=0.0028), 0.01% ointment 15.2% (p=0.2712). The separate atopic dermatitis primary was missed at both doses (0.01% 23.8% and 0.03% 21.4% vs vehicle 11.4%; p=0.0711 and p=0.1290).
NCT04664153: Plaque psoriasis primary, change from baseline in PASI at Week 6, PF-07038124 0.01% once daily vs vehicle: LS mean -4.8 vs 0.1, difference -4.9 (95% CI -7.02 to -2.77), p<0.0001. The atopic dermatitis primary (EASI percent change at Week 6) was also met: -74.9% vs -35.5%, difference -39.4 (95% CI -58.76 to -20.12), p=0.0004.

Large race: only the 78 furthest-along competitors are listed; 46 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(14 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Otezla (apremilast) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 3Recurrent Aphtous StomatitisRecruiting
Est. primary completion 2026-12 · NCT04227314 · CT.gov ↗
What to watch
Phase 4VitiligoEnrolling by invitation
Est. primary completion 2026-12-30 · NCT06593197 · CT.gov ↗
What to watch
Early phase / not applicablePsoriatic ArthritisNot yet recruiting
Est. primary completion 2026-12-30 · NCT07398651 · CT.gov ↗
What to watch
2027 (3)
January 2027 (2)
Phase 1PsoriasisNot yet recruiting
Est. primary completion 2027-01-10 · NCT07908641 · CT.gov ↗
What to watch
Phase 2Alcohol Use Disorder, Alcohol MisuseRecruiting
Est. primary completion 2027-01-31 · NCT07325266 · CT.gov ↗
What to watch
May 2027 (1)
Early phase / not applicablePsoriasisNot yet recruiting
Est. primary completion 2027-05 · NCT07366268 · CT.gov ↗
What to watch
2028 (4)
March 2028 (1)
Phase 3Psoriatic ArthritisRecruiting
Est. primary completion 2028-03-21 · NCT04804553 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP) …Recruiting
Est. primary completion 2028-06 · NCT02735707 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2COVID-19Active not recruiting
Est. primary completion 2028-07-31 · NCT04488081 · CT.gov ↗
What to watch
October 2028 (1)
Phase 1DepressionRecruiting
Est. primary completion 2028-10-03 · NCT05703685 · CT.gov ↗
What to watch
2030 (3)
February 2030 (1)
Phase 3Behçet DiseaseRecruiting
Est. primary completion 2030-02-07 · NCT04528082 · CT.gov ↗
What to watch
June 2030 (1)
Phase 4PsoriasisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07352566 · CT.gov ↗
What to watch
August 2030 (1)
Phase 2Alcohol Use DisorderRecruiting
Est. primary completion 2030-08 · NCT07029529 · CT.gov ↗
What to watch
2036 (1)
March 2036 (1)
Phase 3Psoriatic ArthritisRecruiting
Est. primary completion 2036-03-17 · NCT05767047 · CT.gov ↗
What to watch

See the full readout calendar ↗